<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>Chapter 7 Diabetic kidney disease | LATINART</title>
  <meta name="description" content="A brief index of the landmark trials in nephrology &amp; renal transplant." />
  <meta name="generator" content="bookdown 0.22 and GitBook 2.6.7" />

  <meta property="og:title" content="Chapter 7 Diabetic kidney disease | LATINART" />
  <meta property="og:type" content="book" />
  
  <meta property="og:image" content="/logo.png" />
  <meta property="og:description" content="A brief index of the landmark trials in nephrology &amp; renal transplant." />
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Chapter 7 Diabetic kidney disease | LATINART" />
  
  <meta name="twitter:description" content="A brief index of the landmark trials in nephrology &amp; renal transplant." />
  <meta name="twitter:image" content="/logo.png" />

<meta name="author" content="Robert W Hunter" />


<meta name="date" content="2021-08-03" />

  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="ckd-proteinuria.html"/>
<link rel="next" href="fluids-electrolytes-acid-base.html"/>
<script src="libs/jquery-2.2.3/jquery.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />









<link href="libs/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.0.1/anchor-sections.js"></script>




<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="https://www.kidneyfish.net">KidneyFish</a></li>
<li><a href="./">LATINART</a></li>

<li class="divider"></li>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Preface</a></li>
<li class="chapter" data-level="1" data-path="intro.html"><a href="intro.html"><i class="fa fa-check"></i><b>1</b> Introduction</a></li>
<li class="part"><span><b>I AKI</b></span></li>
<li class="chapter" data-level="2" data-path="aki.html"><a href="aki.html"><i class="fa fa-check"></i><b>2</b> AKI</a><ul>
<li class="chapter" data-level="2.1" data-path="aki.html"><a href="aki.html#aki-trials-in-other-chapters"><i class="fa fa-check"></i><b>2.1</b> AKI trials in other chapters</a></li>
<li class="chapter" data-level="2.2" data-path="aki.html"><a href="aki.html#association-of-aki-with-mortality-morbidity"><i class="fa fa-check"></i><b>2.2</b> Association of AKI with mortality &amp; morbidity</a></li>
<li class="chapter" data-level="2.3" data-path="aki.html"><a href="aki.html#contrast-associated-nephropathy"><i class="fa fa-check"></i><b>2.3</b> Contrast-associated nephropathy</a></li>
<li class="chapter" data-level="2.4" data-path="aki.html"><a href="aki.html#hepatorenal-syndrome"><i class="fa fa-check"></i><b>2.4</b> Hepatorenal syndrome</a></li>
<li class="chapter" data-level="2.5" data-path="aki.html"><a href="aki.html#other-trials-in-aki"><i class="fa fa-check"></i><b>2.5</b> Other trials in AKI</a></li>
</ul></li>
<li class="part"><span><b>II CKD</b></span></li>
<li class="chapter" data-level="3" data-path="renal-anaemia.html"><a href="renal-anaemia.html"><i class="fa fa-check"></i><b>3</b> Renal anaemia</a><ul>
<li class="chapter" data-level="3.1" data-path="renal-anaemia.html"><a href="renal-anaemia.html#erythropoetin"><i class="fa fa-check"></i><b>3.1</b> Erythropoetin</a></li>
<li class="chapter" data-level="3.2" data-path="renal-anaemia.html"><a href="renal-anaemia.html#iron"><i class="fa fa-check"></i><b>3.2</b> Iron</a></li>
</ul></li>
<li class="chapter" data-level="4" data-path="ckd-mbd.html"><a href="ckd-mbd.html"><i class="fa fa-check"></i><b>4</b> CKD-MBD</a><ul>
<li class="chapter" data-level="4.1" data-path="ckd-mbd.html"><a href="ckd-mbd.html#cinacalcet"><i class="fa fa-check"></i><b>4.1</b> Cinacalcet</a></li>
<li class="chapter" data-level="4.2" data-path="ckd-mbd.html"><a href="ckd-mbd.html#phosphate-binders"><i class="fa fa-check"></i><b>4.2</b> Phosphate binders</a></li>
</ul></li>
<li class="part"><span><b>III Blood pressure &amp; proteinuria</b></span></li>
<li class="chapter" data-level="5" data-path="HTN-CVS.html"><a href="HTN-CVS.html"><i class="fa fa-check"></i><b>5</b> Hypertension &amp; cardiovascular risk</a><ul>
<li class="chapter" data-level="5.1" data-path="HTN-CVS.html"><a href="HTN-CVS.html#hypertension"><i class="fa fa-check"></i><b>5.1</b> Hypertension</a></li>
<li class="chapter" data-level="5.2" data-path="HTN-CVS.html"><a href="HTN-CVS.html#statins"><i class="fa fa-check"></i><b>5.2</b> Statins</a></li>
<li class="chapter" data-level="5.3" data-path="HTN-CVS.html"><a href="HTN-CVS.html#cardiovascular-risk"><i class="fa fa-check"></i><b>5.3</b> Cardiovascular risk</a></li>
<li class="chapter" data-level="5.4" data-path="HTN-CVS.html"><a href="HTN-CVS.html#renal-dennervation"><i class="fa fa-check"></i><b>5.4</b> Renal dennervation</a></li>
<li class="chapter" data-level="5.5" data-path="HTN-CVS.html"><a href="HTN-CVS.html#renovascular-disease"><i class="fa fa-check"></i><b>5.5</b> Renovascular disease</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="ckd-proteinuria.html"><a href="ckd-proteinuria.html"><i class="fa fa-check"></i><b>6</b> CKD &amp; proteinuria</a><ul>
<li class="chapter" data-level="6.1" data-path="ckd-proteinuria.html"><a href="ckd-proteinuria.html#egfr-calculation"><i class="fa fa-check"></i><b>6.1</b> eGFR calculation</a></li>
<li class="chapter" data-level="6.2" data-path="ckd-proteinuria.html"><a href="ckd-proteinuria.html#association-of-egfr-and-proteinuria-with-hard-outcomes"><i class="fa fa-check"></i><b>6.2</b> Association of eGFR and proteinuria with hard outcomes</a></li>
<li class="chapter" data-level="6.3" data-path="ckd-proteinuria.html"><a href="ckd-proteinuria.html#competing-risk-of-death"><i class="fa fa-check"></i><b>6.3</b> Competing risk of death</a></li>
<li class="chapter" data-level="6.4" data-path="ckd-proteinuria.html"><a href="ckd-proteinuria.html#rasi-progression-in-non-diabetic-disease"><i class="fa fa-check"></i><b>6.4</b> RASi &amp; progression in non-diabetic disease</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html"><i class="fa fa-check"></i><b>7</b> Diabetic kidney disease</a><ul>
<li class="chapter" data-level="7.1" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#glycaemic-control"><i class="fa fa-check"></i><b>7.1</b> Glycaemic control</a></li>
<li class="chapter" data-level="7.2" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#DKD_RASi"><i class="fa fa-check"></i><b>7.2</b> RAS blockade</a></li>
<li class="chapter" data-level="7.3" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#drasi_DKD"><i class="fa fa-check"></i><b>7.3</b> Dual RAAS blockade</a></li>
<li class="chapter" data-level="7.4" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#sglti"><i class="fa fa-check"></i><b>7.4</b> SGLTi</a></li>
</ul></li>
<li class="part"><span><b>IV BODY FLUIDS</b></span></li>
<li class="chapter" data-level="8" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html"><i class="fa fa-check"></i><b>8</b> Fluids, electrolytes &amp; acid-base</a><ul>
<li class="chapter" data-level="8.1" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#hyponatraemia"><i class="fa fa-check"></i><b>8.1</b> Hyponatraemia</a></li>
<li class="chapter" data-level="8.2" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#hyperkalaemia"><i class="fa fa-check"></i><b>8.2</b> Hyperkalaemia</a></li>
<li class="chapter" data-level="8.3" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#fluids"><i class="fa fa-check"></i><b>8.3</b> IV fluid therapy</a></li>
<li class="chapter" data-level="8.4" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#diuretic-therapy"><i class="fa fa-check"></i><b>8.4</b> Diuretic therapy</a></li>
<li class="chapter" data-level="8.5" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#metabolic-acidosis"><i class="fa fa-check"></i><b>8.5</b> Metabolic acidosis</a><ul>
<li class="chapter" data-level="8.5.1" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#acidosis-of-ckd"><i class="fa fa-check"></i><b>8.5.1</b> Acidosis of CKD</a></li>
<li class="chapter" data-level="8.5.2" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#renal-tubular-acidosis"><i class="fa fa-check"></i><b>8.5.2</b> Renal tubular acidosis</a></li>
<li class="chapter" data-level="8.5.3" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#severe-metabolic-acidosis"><i class="fa fa-check"></i><b>8.5.3</b> Severe metabolic acidosis</a></li>
</ul></li>
</ul></li>
<li class="part"><span><b>V SPECIFIC KIDNEY DISEASES</b></span></li>
<li class="chapter" data-level="9" data-path="glomerular-disease.html"><a href="glomerular-disease.html"><i class="fa fa-check"></i><b>9</b> Glomerular disease</a><ul>
<li class="chapter" data-level="9.1" data-path="glomerular-disease.html"><a href="glomerular-disease.html#proteinuria"><i class="fa fa-check"></i><b>9.1</b> Proteinuria</a></li>
<li class="chapter" data-level="9.2" data-path="glomerular-disease.html"><a href="glomerular-disease.html#igan"><i class="fa fa-check"></i><b>9.2</b> IgAN</a></li>
<li class="chapter" data-level="9.3" data-path="glomerular-disease.html"><a href="glomerular-disease.html#membranous"><i class="fa fa-check"></i><b>9.3</b> Membranous</a></li>
<li class="chapter" data-level="9.4" data-path="glomerular-disease.html"><a href="glomerular-disease.html#minimal-change"><i class="fa fa-check"></i><b>9.4</b> Minimal change</a></li>
<li class="chapter" data-level="9.5" data-path="glomerular-disease.html"><a href="glomerular-disease.html#fsgs"><i class="fa fa-check"></i><b>9.5</b> FSGS</a></li>
<li class="chapter" data-level="9.6" data-path="glomerular-disease.html"><a href="glomerular-disease.html#Apol1"><i class="fa fa-check"></i><b>9.6</b> APOL1 nephropathy</a></li>
<li class="chapter" data-level="9.7" data-path="glomerular-disease.html"><a href="glomerular-disease.html#ahus"><i class="fa fa-check"></i><b>9.7</b> aHUS</a></li>
</ul></li>
<li class="chapter" data-level="10" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html"><i class="fa fa-check"></i><b>10</b> ANCA vasculitis</a><ul>
<li class="chapter" data-level="10.1" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#induction"><i class="fa fa-check"></i><b>10.1</b> Induction</a><ul>
<li class="chapter" data-level="10.1.1" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#glucocorticoids-plasma-exchange"><i class="fa fa-check"></i><b>10.1.1</b> Glucocorticoids &amp; Plasma-exchange</a></li>
<li class="chapter" data-level="10.1.2" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#cyclophosphamide"><i class="fa fa-check"></i><b>10.1.2</b> Cyclophosphamide</a></li>
<li class="chapter" data-level="10.1.3" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#rituximab"><i class="fa fa-check"></i><b>10.1.3</b> Rituximab</a></li>
<li class="chapter" data-level="10.1.4" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#other-agents"><i class="fa fa-check"></i><b>10.1.4</b> Other agents</a></li>
</ul></li>
<li class="chapter" data-level="10.2" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#maintenance"><i class="fa fa-check"></i><b>10.2</b> Maintenance</a></li>
<li class="chapter" data-level="10.3" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#adjunctive-therapies"><i class="fa fa-check"></i><b>10.3</b> Adjunctive therapies</a></li>
</ul></li>
<li class="chapter" data-level="11" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html"><i class="fa fa-check"></i><b>11</b> Lupus nephritis</a><ul>
<li class="chapter" data-level="11.1" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#induction-1"><i class="fa fa-check"></i><b>11.1</b> Induction</a></li>
<li class="chapter" data-level="11.2" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#maintenance-1"><i class="fa fa-check"></i><b>11.2</b> Maintenance</a></li>
<li class="chapter" data-level="11.3" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#newer-therapies"><i class="fa fa-check"></i><b>11.3</b> Newer therapies</a></li>
</ul></li>
<li class="chapter" data-level="12" data-path="adpkd.html"><a href="adpkd.html"><i class="fa fa-check"></i><b>12</b> ADPKD</a><ul>
<li class="chapter" data-level="12.1" data-path="adpkd.html"><a href="adpkd.html#blood-pressure-targets-and-rasi"><i class="fa fa-check"></i><b>12.1</b> Blood pressure targets and RASi</a></li>
<li class="chapter" data-level="12.2" data-path="adpkd.html"><a href="adpkd.html#vasopressin-antagonist-therapy"><i class="fa fa-check"></i><b>12.2</b> Vasopressin antagonist therapy</a></li>
</ul></li>
<li class="chapter" data-level="13" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html"><i class="fa fa-check"></i><b>13</b> Miscellaneous conditions</a><ul>
<li class="chapter" data-level="13.1" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#myeloma"><i class="fa fa-check"></i><b>13.1</b> Myeloma</a></li>
<li class="chapter" data-level="13.2" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#pregnancy"><i class="fa fa-check"></i><b>13.2</b> Pregnancy</a></li>
<li class="chapter" data-level="13.3" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#ain"><i class="fa fa-check"></i><b>13.3</b> AIN</a></li>
<li class="chapter" data-level="13.4" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#tuberous-sclerosis"><i class="fa fa-check"></i><b>13.4</b> Tuberous sclerosis</a></li>
<li class="chapter" data-level="13.5" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#other"><i class="fa fa-check"></i><b>13.5</b> Other</a></li>
</ul></li>
<li class="part"><span><b>VI RRT &amp; TRANSPLANT</b></span></li>
<li class="chapter" data-level="14" data-path="acute-RRT.html"><a href="acute-RRT.html"><i class="fa fa-check"></i><b>14</b> Acute dialysis</a><ul>
<li class="chapter" data-level="14.1" data-path="acute-RRT.html"><a href="acute-RRT.html#dose"><i class="fa fa-check"></i><b>14.1</b> Dose</a></li>
<li class="chapter" data-level="14.2" data-path="acute-RRT.html"><a href="acute-RRT.html#timing"><i class="fa fa-check"></i><b>14.2</b> Timing</a></li>
</ul></li>
<li class="chapter" data-level="15" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html"><i class="fa fa-check"></i><b>15</b> Chronic dialysis</a><ul>
<li class="chapter" data-level="15.1" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#chronic-haemodialysis"><i class="fa fa-check"></i><b>15.1</b> Chronic Haemodialysis</a><ul>
<li class="chapter" data-level="15.1.1" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#modality"><i class="fa fa-check"></i><b>15.1.1</b> Modality</a></li>
<li class="chapter" data-level="15.1.2" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#dose-1"><i class="fa fa-check"></i><b>15.1.2</b> Dose</a></li>
<li class="chapter" data-level="15.1.3" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#initiation"><i class="fa fa-check"></i><b>15.1.3</b> Initiation</a></li>
</ul></li>
<li class="chapter" data-level="15.2" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#peritoneal-dialysis"><i class="fa fa-check"></i><b>15.2</b> Peritoneal Dialysis</a></li>
</ul></li>
<li class="chapter" data-level="16" data-path="transplant.html"><a href="transplant.html"><i class="fa fa-check"></i><b>16</b> Transplant</a><ul>
<li class="chapter" data-level="16.1" data-path="transplant.html"><a href="transplant.html#donors"><i class="fa fa-check"></i><b>16.1</b> Donors</a><ul>
<li class="chapter" data-level="16.1.1" data-path="transplant.html"><a href="transplant.html#donor-types"><i class="fa fa-check"></i><b>16.1.1</b> Donor types</a></li>
<li class="chapter" data-level="16.1.2" data-path="transplant.html"><a href="transplant.html#donor-aki"><i class="fa fa-check"></i><b>16.1.2</b> Donor AKI</a></li>
<li class="chapter" data-level="16.1.3" data-path="transplant.html"><a href="transplant.html#ischaemic-time"><i class="fa fa-check"></i><b>16.1.3</b> Ischaemic time</a></li>
</ul></li>
<li class="chapter" data-level="16.2" data-path="transplant.html"><a href="transplant.html#immunosuppression"><i class="fa fa-check"></i><b>16.2</b> Immunosuppression</a></li>
<li class="chapter" data-level="16.3" data-path="transplant.html"><a href="transplant.html#desensitisation"><i class="fa fa-check"></i><b>16.3</b> Desensitisation</a></li>
<li class="chapter" data-level="16.4" data-path="transplant.html"><a href="transplant.html#cmv-disease"><i class="fa fa-check"></i><b>16.4</b> CMV disease</a></li>
<li class="chapter" data-level="16.5" data-path="transplant.html"><a href="transplant.html#statin_Tx"><i class="fa fa-check"></i><b>16.5</b> CVS risk</a></li>
<li class="chapter" data-level="16.6" data-path="transplant.html"><a href="transplant.html#rejection"><i class="fa fa-check"></i><b>16.6</b> Rejection</a></li>
</ul></li>
<li class="part"><span><b>VII OTHER</b></span></li>
<li class="chapter" data-level="17" data-path="historic-trials.html"><a href="historic-trials.html"><i class="fa fa-check"></i><b>17</b> Historic trials</a></li>
<li class="chapter" data-level="18" data-path="seminal-basic-science.html"><a href="seminal-basic-science.html"><i class="fa fa-check"></i><b>18</b> Seminal basic science</a></li>
<li class="chapter" data-level="19" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html"><i class="fa fa-check"></i><b>19</b> Other (non-renal) specialties</a><ul>
<li class="chapter" data-level="19.1" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html#critical-care"><i class="fa fa-check"></i><b>19.1</b> Critical care</a><ul>
<li class="chapter" data-level="19.1.1" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html#sepsis"><i class="fa fa-check"></i><b>19.1.1</b> Sepsis</a></li>
</ul></li>
<li class="chapter" data-level="19.2" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html#cardio"><i class="fa fa-check"></i><b>19.2</b> Cardiology</a></li>
<li class="chapter" data-level="19.3" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html#haematology"><i class="fa fa-check"></i><b>19.3</b> Haematology</a></li>
</ul></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">LATINART</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="diabetic-kidney-disease" class="section level1">
<h1><span class="header-section-number">Chapter 7</span> Diabetic kidney disease</h1>
<div id="glycaemic-control" class="section level2">
<h2><span class="header-section-number">7.1</span> Glycaemic control</h2>
<p><strong>Intensive glycaemic control</strong> slows progression of diabetic nephropathy.</p>

<div class="box_landmark">
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/8366922"><strong>DCCT</strong></a> (1993): <img src="Logo_RCT.png" style="height:1.2em" /> <img src="Logo_SEM.png" style="height:1.2em" /> - intensive <em>vs.</em> conventional insulin therapy in T1DM (achieving HbA1c ~7 <em>vs.</em> ~9 %). Intensive control reduced risk of micro- and overt albuminuria (and retinopathy). Frequent hypos in the intensive group (in the era of isophane insulin).</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/9742976"><strong>UKPDS 33</strong></a> (1998): <img src="Logo_RCT.png" style="height:1.2em" /> <img src="Logo_SEM.png" style="height:1.2em" /> - intensive <em>vs.</em> conventional glycaemic control in T2DM (achieving HbA1c ~7.0 <em>vs.</em> ~7.9 %; n ~5000). Intensive control reduced risk of microalbuminuria.</p>
<p>10-year follow-up data from UKPDS (in 2008) showed that early good <a href="https://www.ncbi.nlm.nih.gov/pubmed/18784090"><strong>glycaemic</strong></a> control exerted a beneficial “legacy” effect on micro-vascular outcomes, MI and death whereas early good <a href="https://www.ncbi.nlm.nih.gov/pubmed/18784091"><strong>ABP</strong></a> control did not exert a legacy benefit.</p>
</div>

<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/28187983"><strong>STENO-2</strong></a> (2017): <img src="Logo_RCT.png" style="height:1.2em" /> conventional management <em>vs.</em> multi-factorial intervention in T2DM with microalbuminuria. Multi-factorial intervention conferred benefits for nephropathy, retinopathy and autonomic neuropathy.</p>
</div>
<div id="DKD_RASi" class="section level2">
<h2><span class="header-section-number">7.2</span> RAS blockade</h2>
<p>RASi slow progression in DM with <strong>overt albuminuria</strong>.</p>

<div class="box_landmark">
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/8413456"><strong>Lewis et al.</strong></a> (1993): <img src="Logo_RCT.png" style="height:1.2em" /> <img src="Logo_SEM.png" style="height:1.2em" /> - captopril <em>vs.</em> placebo in T1DM with PER &gt; 0.5 g/day. Captopril delayed time to doubling of SCr and reduced risk of composite of death and ESRF independent of effects on blood pressure.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/11565517"><strong>IDNT</strong></a> (2001): <img src="Logo_RCT.png" style="height:1.2em" /> <img src="Logo_SEM.png" style="height:1.2em" /> - irbesartan <em>vs.</em> amlodipine <em>vs.</em> placebo in T2DM with HTN and PER &gt; 0.9 g/day. Irbesartan reduced risk of composite (doubling of SCr, ESRF, death) compared to both other groups. Effects independent of blood-pressure.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/11565518"><strong>RENAAL</strong></a> (2001): <img src="Logo_RCT.png" style="height:1.2em" /> <img src="Logo_SEM.png" style="height:1.2em" /> - losartan <em>vs.</em> placebo in T2DM and ACR &gt; 30 or PER &gt; 0.5 g/day. Losartan reduced risk of composite end-point (doubling SCr, ESRF, death). Effects independent of blood-pressure.</p>
</div>

<p>RASi slow progression to overt nephropathy in <strong>microalbuminuria</strong>:</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/11242497"><strong>ACEi in DN Trialist Group</strong></a> (2001): <img src="Logo_MET.png" style="height:1.2em" /> - ACEi delay progression to overt albuminuria in T1DM and microalbuminuria.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/11565519"><strong>Parving et al.</strong></a> (2001): <img src="Logo_RCT.png" style="height:1.2em" /> - irbesartan <em>vs.</em> placebo in T2DM with HTN and microalbuminuria. Irbesartan delayed progression to overt albuminuria.</p>
<p>Are RASi beneficial even <strong>before the onset of microalbuminuria</strong>?</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/21388309"><strong>ROADMAP</strong></a> (2011): <img src="Logo_RCT.png" style="height:1.2em" /> - olmesartan <em>vs.</em> placebo in T2DM without microalbuminuria. In the olmesartan group, there was delayed onset of microalbuminuria but a greater number of cardiovascular deaths.</p>
</div>
<div id="drasi_DKD" class="section level2">
<h2><span class="header-section-number">7.3</span> Dual RAAS blockade</h2>
<p>Dual RAAS blockade increases the risk of adverse events:</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/24206457"><strong>VA NEPHRON-D</strong></a> (2013): <img src="Logo_RCT.png" style="height:1.2em" /> - losartan plus placebo <em>vs</em> losartan plus lisinopril in T2DM and ACR &gt; 30. Terminated early for safety concerns. No benefit from dual RAS blockade (on composite of change in eGFR, ESRF and mortality) but increased risk of AKI and hyperkalaemia.</p>
<p>See also ONTARGET trial in <a href="HTN-CVS.html#HTN_CVS">hypertension chapter</a>.
See also CO-OPERATE trial (retracted).</p>
</div>
<div id="sglti" class="section level2">
<h2><span class="header-section-number">7.4</span> SGLTi</h2>

<div class="box_landmark">
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/30990260"><strong>CREDENCE</strong></a> (2019): <img src="Logo_RCT.png" style="height:1.2em" /> <img src="Logo_SEM.png" style="height:1.2em" /> - canagliflozin 100 mg od <em>vs.</em> placebo in T2DM with eGFR 30–90 (predominantly eGFR 30–60) and uACR &gt;30. Mean GFR 56; median uACR 90. Primary composite outcome (ESKD, doubling of SCr, death from renal or CVS cause). Terminated early (median follow-up 2.6 yrs) because of efficacy. RR of primary outcome 30% lower in flozin group. Also reductions in risk of ESKD, CVS death, MI, CVA, hospitalisation for CCF.</p>
</div>

<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/27299675"><strong>EMPA-REG</strong></a> (2016): <img src="Logo_RCT.png" style="height:1.2em" /> - empagliflozin <em>vs.</em> placebo in T2DM with eGFR &gt;30. Mean GFR 74; ACR &lt; 3 in 60%. Empagliflozin slowed rate of decline in eGFR and progression to ESRF.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/29133604"><strong>CANVAS</strong></a> (2018): <img src="Logo_RCT.png" style="height:1.2em" /> - canagliflozin <em>vs.</em> placebo in T2DM for primary and secondary prevention of CVS events and renal composite outcome (40% reducing in eGFR, RRT, death). Canagliflozin reduced CVS and renal events in both primary and secondary prevention cohorts.</p>

</div>
</div>



            </section>

          </div>
        </div>
      </div>
<a href="ckd-proteinuria.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="fluids-electrolytes-acid-base.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/lunr.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": null,
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 1
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"toc": {
"collapse": "section"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
